San Diego, CA, United States

La jolla Pharmaceutical

ljpc.com
San Diego, CA, United States
SEARCH FILTERS
Time filter
Source Type

Patent
La jolla Pharmaceutical | Date: 2017-01-27

Various aspects of the invention relate to compositions comprising C-2a gentamicin. A composition may be substantially free from one or more of C-1 gentamicin, C-1a gentamicin, C-2 gentamicin, C-2b gentamicin, gentamicin A, gentamicin B, and gentamicin X. In some aspects, the invention relates to a method for treating a condition in a subject, comprising administering a composition comprising C-2a gentamicin to the subject. The condition may be, for example, a bacterial infection, genetic disease or disorder, or cancer.


Patent
La jolla Pharmaceutical | Date: 2017-01-06

The present disclosure relates to the use of angiotensin II, angiotensin III, or angiotensin IV in therapeutic methods for the treatment of hypotension, especially catecholamine-resistant hypotension.


Patent
La jolla Pharmaceutical | Date: 2017-02-08

The invention provides methods for the treatment of a kidney disorder, such as chronic kidney disease or NASH, using a galectine-3 inhibitor, such as a modified pectin (e.g., GCS-100). Also described are methods for assessing and/or monitoring the effects of a galectin-3 inhibitor, e.g., to adapt the dosing regimen of the inhibitor during therapy.


Patent
La jolla Pharmaceutical | Date: 2016-02-26

The present invention is directed to methods and compositions for augmenting treatment of cancers and other proliferative disorders. In particular embodiments, the invention combines the administration of an agent that inhibits the anti-apoptotic activity of galectin-3 (e.g., a galectin-3 inhibitor) so as to potentiate the toxicity of a chemotherapeutic agent. In certain preferred embodiments, the conjoint therapies of the present invention can be used to improve the efficacy of those chemotherapeutic agents whose cytotoxicity is influenced by the status of an anti-apoptotic Bcl-2 protein for the treated cell. For instance, galectin-3 inhibitors can be administered in combination with a chemotherapeutic agent that interferes with DNA replication fidelity or cell-cycle progression of cells undergoing unwanted proliferation.


Patent
La jolla Pharmaceutical | Date: 2014-04-16

The present invention provides compositions of modified pectin and methods for preparing and using them.


Patent
La jolla Pharmaceutical | Date: 2014-01-29

The present invention is directed to methods and compositions for augmenting treatment of cancers and other proliferative disorders. In particular embodiments, the invention combines the administration of an agent that inhibits the anti-apoptotic activity of galectin-3 (e.g., a galectin-3 inhibitor) so as to potentiate the toxicity of a chemotherapeutic agent. In certain preferred embodiments, the conjoint therapies of the present invention can be used to improve the efficacy of those chemotherapeutic agents whose cytotoxicity is influenced by the status of an anti-apoptotic Bcl-2 protein for the treated cell. For instance, galectin-3 inhibitors can be administered in combination with a chemotherapeutic agent that interferes with DNA replication fidelity or cell-cycle progression of cells undergoing unwanted proliferation.


Patent
La jolla Pharmaceutical | Date: 2015-07-08

The present disclosure relates to the use of angiotensin II in therapeutic methods for the treatment of hypotension, especially catecholamine-resistant hypotension.


Patent
La jolla Pharmaceutical | Date: 2015-03-10

The invention provides methods for the treatment of diseases and conditions relating to galectin 3 using a galectin-3 inhibitor, such as a modified pectin (e.g., GCS-100). Also described are methods for conjoint therapy, and methods for assessing and/or monitoring the effects of a galectin-3 inhibitor, e.g., to adapt the dosing regimen of the inhibitor during therapy.


Patent
La jolla Pharmaceutical | Date: 2016-09-30

The present disclosure relates to the use of angiotensin II in therapeutic methods for the treatment of renal failure, especially renal failure associated with cirrhosis.


Patent
La jolla Pharmaceutical | Date: 2015-10-07

The Present invention provides compositions of modified pectin, e.g. having a molecular weight of 50 to 200kD and preferably 80 to 150kD, the method for preparing them and their use to inhibit cell proliferation in a patient.

Loading La jolla Pharmaceutical collaborators
Loading La jolla Pharmaceutical collaborators